Navigation Links
Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced positive preliminary results from a multicenter Phase 2 clinical study of its lead clinical candidate, Lymphoseek(R) (Technetium Tc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietary radioactive targeting agent being developed for use with handheld gamma detection devices, such as Neoprobe's neo2000(R) system, in a surgical procedure known as Sentinel Lymph Node Biopsy (SLNB). The primary endpoint of this multicenter, single-arm, open-label, within-patient, single-dose, multi-stage trial measured the rate at which Lymphoseek localized to lymphoid tissue with a goal of achieving 90% localization. In results reported today, localization of Lymphoseek to lymphoid tissue was observed in over 94% of the SLNB procedures performed as a part of the Phase 2 trial in patients with either breast cancer or melanoma.

This study is being conducted at five of the leading cancer centers in the U.S.: John Wayne Cancer Center; M.D. Anderson, the University of California, San Francisco; University Hospitals - Cleveland (Case Western Reserve); and the University of Louisville. Positive interim results from the trial were announced earlier this year. Neoprobe also reported that no drug-related significant adverse events have been noted in results analyzed to-date. Neoprobe now plans to begin winding down Phase 2 trial activities, collecting the required 30-day patient safety follow-up information and accumulating data to report to FDA. In parallel, Neoprobe is also preparing to submit its Phase 3 pivotal trial protocol to FDA.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Neoprobe Phase Lymphoseek Trial Meets Primary Endpoint
(Date:10/30/2014)... YORK , Oct. 30, 2014  The number ... States is growing steadily, thanks to drug ... as a result of the economic downturn, retail clinic ... a year of opportunities, as the number of retail ... researcher,s report, Retail Clinics Market Overview and 2014 ...
(Date:10/30/2014)... Molecular Profiles Ltd., a subsidiary of Columbia ... Maryland -based Xceleron have announced a collaboration ... development that will be launched at AAPS in ... This partnership extends Molecular Profiles, new ROADMAP to Clinical ... month. The company also has complementary collaborations in place ...
(Date:10/30/2014)... LOS ANGELES , Oct. 30, 2014 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... technology and its lead drug candidate, aldoxorubicin.  The ... A New Approach," will be given by ... the Sarcoma Oncology Center and principal investigator of ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR ) ... for the quarter ended December 31, 2010 before market ... and Chief Executive Officer, Randall Kaye, M.D., Senior Vice ... President, Finance, will host an investment community conference call ...
... 27, 2011 Higher volume drove four ... in Q4 led to growth in operating income. ... (non-GAAP). Full-year 2010 revenue topped $23 billion as ... exceed $1 billion in annual sales. Full-year 2010 ...
Cached Medicine Technology:Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 2Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 3Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 4Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 5Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 6Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 7Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 8Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 9Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 10Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 11Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 12Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 13Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 14Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 15Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 16Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 17Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 18Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 19Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 20Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance 21
(Date:10/30/2014)... Florida (PRWEB) October 30, 2014 Timothy, ... visit to Pompano Beach firefighters, showing that you are ... , Timothy met firefighters Tracey and Carl at ... Galuppi’s Restaurant and the Pompano Beach Chamber of Commerce. ... the fire truck, letting Timothy wear his real fireman’s ...
(Date:10/30/2014)... High efficacy and low irritation ... medical-grade skin care domain: Cosmederm, the specialty biotechnology ... topical dermatological products, today announces the launch of ... patented COSMEDERM®-7 anti-irritant technology. , Formulated with ... 70%) and a low pH (pH 1.2 and ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Paramount Rx, ... care, is increasing efforts to help people save money ... continue to increase for prescription drugs in the new ... savings and resources to bridge the relationship between consumers, ... of the biggest challenges people face today with medical ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, ... genes have been identified that appear linked to autism ... say they are on their way to discovering up ... disorder. Autism spectrum disorders include a range of ... repetitive behaviors. An estimated one in 68 U.S. children ...
(Date:10/30/2014)... 2014 Dr. Joseph Furlin MD, a certified ... his practices; OB GYN in Melrose Park, IL ... website contains important information about each of the care services ... patient forms in English and Spanish. The navigation of ... on the website provide Dr. Furlin’s patients with important information ...
Breaking Medicine News(10 mins):Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... , , Cuts Will ... to Recent Cuts , , ... Chairman Max Baucus (D-Mont.) issued his recommendations for healthcare reform in ... bill contains several provisions that affect home medical equipment, ranging from ...
... remain unknown, expert says, , WEDNESDAY, Sept. 16 (HealthDay News) ... for older women: stopping hot flashes. , In a ... the New England Journal of Medicine , researchers from ... cetrorelix (Cetrotide) helped ease hot flash symptoms. , "It ...
... obesity, but beverage industry balks at proposal , WEDNESDAY, Sept. ... per ounce of soda and other sugary drinks could stem ... first year alone, health experts say. , That windfall could ... to prevent obesity, say a group of prominent researchers in ...
... , NEW YORK, Sept. 16 As ... If the thought of skinny jeans has you feeling uneasy, think ... you into those new jeans. , , Listen ... , , Registered journalists can access video, audio, ...
... , , MINNEAPOLIS, Sept. 16 ... Board Members and thanked outgoing members for their service to the ... was elected as the new Board Chair. The full roster of ... David Fisher, Board Chair - ...
... , THE GLOBALIZATION PLATFORM ... More than 120 delegates, including heads of state, acclaimed artists, Nobel ... City for the fourth annual Global Creative Leadership Summit , ... globalization. Organized by the Louise Blouin Foundation , an international ...
Cached Medicine News:Health News:Senate Finance Committee Cuts Home Medical Equipment in Reform Package 2Health News:Fertility Drug Shows Potential Against Hot Flashes 2Health News:Fertility Drug Shows Potential Against Hot Flashes 3Health News:'Soda Tax' Wins Health Experts' Support 2Health News:'Soda Tax' Wins Health Experts' Support 3Health News:'Soda Tax' Wins Health Experts' Support 4Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:Global Creative Leadership Summit 23-25 September 2009 2Health News:Global Creative Leadership Summit 23-25 September 2009 3
For accurately monitoring core temperature and heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
... Level 1 enables hospitals ... patient monitors to a ... Our temperature monitoring disposale ... are superior in their ...
Medicine Products: